Opinion|Videos|December 23, 2024
Final Thoughts: The Spesolimab and GPP Flare Reduction
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on Dermatology Times
1
How Emerging Androgenetic Alopecia Therapies Target DHT at the Scalp Level
2
Tildrakizumab Partially Reverses Epigenetic Aging in Psoriasis, Pilot Study Shows
3
Field-Directed Therapy Favored for Actinic Keratosis Management
4
Diet Linked to Improved Chronic Idiopathic Urticaria Control
5